Introduction {#s1}
============

Epilepsy is a common presenting symptom of primary brain tumors, particularly low-grade gliomas (LGGs). Most patients with LGGs experience epileptic seizures at disease onset [@pone.0046218-Lee1]--[@pone.0046218-Leighton1], but not all have seizures, despite having similar histology and tumor location. This suggests that some distinct molecular genetic characteristics may exist for tumors causing different clinical symptoms. The presence of seizures may, to some extent, be related to the biological behavior of gliomas. Seizures play an important role in patients\' postoperative quality of life [@pone.0046218-Leighton1], especially the patients with LGGs because of the duration of their survival. Although more than half of the patients with LGGs may have favorable seizure prognosis after surgery, about 30% of these patients suffer from uncontrolled seizures in spite of treatment with different antiepileptic drugs (AEDs) [@pone.0046218-Chang1], [@pone.0046218-Schaller1].

MicroRNAs (miRNAs) are single-stranded non-coding RNAs recognized as endogenous regulators of post-transcriptional gene expression. These small RNAs are capable of controlling gene expression by mediating either mRNA degradation or translation inhibition [@pone.0046218-Bartel1]. Several miRNAs have been found in the human brain, and they play a crucial role in a wide range of biological processes, such as regulation of the innate and adaptive immune response [@pone.0046218-Pedersen1], [@pone.0046218-Pauley1]. MiRNAs are implicated in maintaining the cell fate of immune cells (e.g. miR-181a/223), and they are involved in innate immunity by regulating Toll-like receptor signaling and ensuing cytokine response (e.g. miR-146). Furthermore, miRNAs regulate central elements of the adaptive immune response such as antigen presentation (e.g. miR-155). Increasing evidence highlights the functions of miRNAs that participate in the underlying molecular mechanisms of neurological diseases, such as Parkinson\'s disease and Alzheimer\'s disease [@pone.0046218-Lukiw1], [@pone.0046218-Hbert1]. These small non-coding RNAs may provide opportunities for diagnosis and treatment of a damaged nervous system. There are numerous reports supporting the involvement of inflammatory and immune processes in temporal lobe epilepsy (TLE) [@pone.0046218-Vezzani1], [@pone.0046218-Aronica1]. However, there are no published studies regarding the roles of miRNAs in tumor-related epilepsy, a major neurological disorder affecting nearly ten million people worldwide.

Previous studies have indicated that miR-196b may be a prognostic predictor in glioblastoma (GBM) patients [@pone.0046218-Guan1], [@pone.0046218-Ma1]. Here, we report the expression pattern of miR-196b using the expression values from microarrays of 23 astrocytoma tissues. This result was validated in an independent cohort containing 83 samples. Subsequently, a miR-196b-associated gene-expression profile was characterized by some enrichment of genes related to transcription and cell cycles.

Methods {#s2}
=======

Patients and tissue samples {#s2a}
---------------------------

This study was approved by the Ethics Committee of Beijing Tiantan Hospital and written informed consent was obtained from all the patients included. Between September 2005 and June 2009, 1134 patients with LGGs were treated at the Glioma Treatment Center of Tiantan Hospital (Beijing, China). Of these patients, 508 (\>16-years-old) underwent primary resection of supratentorial LGGs. All patients were pathologically confirmed and diagnosed as having WHO Grade II gliomas, including 48 oligodendrogliomas (O), 229 astrocytomas (A) and 231 oligoastrocytomas (OA). Tissue samples were recovered immediately after surgery, snap-frozen using liquid nitrogen vapors and stored at −80°C until needed. For the purpose of creating more homogeneous sample conditions, only samples that strictly met the following criteria were selected: 1) age \<55-years-old; 2) no medication involving AEDs before admission; 3) a single lesion mainly focused at the frontal lobe as determined by MRI; and 4) pure WHO grade II astrocytomas by histopathology. We excluded older patients (≥55-years-old), patients on AEDs medication before admission, patients with partial or occipital lobe or 3 lobes of tumor location, as well as those with secondary resection or needle biopsy only. To make a comparison between seizure and non-seizure tissue, we defined the 2 groups as the seizure (patients who had secondary generalized seizure once or twice) and non-seizure (patients who demonstrated non-seizure symptoms for more than 6 months) groups. Twenty-three samples were eventually included for whole genome miRNA microarray analysis ([Figure 1](#pone-0046218-g001){ref-type="fig"}). Each of these samples was proved to contain \>80% of tumor cells. The clinical features of these cases are summarized in [Table 1](#pone-0046218-t001){ref-type="table"}. Another 83 samples, including O, A, and OA were obtained for validation using quantitative reverse-transcriptase polymerase chain reaction (q-PCR) analysis ([Table 2](#pone-0046218-t002){ref-type="table"}).

![Procedure for the selection of 23 samples used for whole genome microRNA profiling.](pone.0046218.g001){#pone-0046218-g001}

10.1371/journal.pone.0046218.t001

###### Summary of clinical data.

![](pone.0046218.t001){#pone-0046218-t001-1}

  Patients                               Gender/Age (yrs)   Seizures   Duration of disease (days)   Seizure type   Tumor location[a](#nt101){ref-type="table-fn"}   Diagnosis
  ------------------------------------- ------------------ ---------- ---------------------------- -------------- ------------------------------------------------ -----------
  P1                                           F/37           Yes                  6                    SGS                              FT                           II A
  P2                                           M/30           Yes                  4                    SGS                              F                            II A
  P3[b](#nt104){ref-type="table-fn"}           F/30           Yes                  6                    SGS                              F                            II A
  P4                                           M/44           Yes                  10                   SGS                              F                            II A
  P5                                           M/24           Yes                  14                   SGS                              FT                           II A
  P6[b](#nt104){ref-type="table-fn"}           F/36           Yes                  1                    SGS                              F                            II A
  P7                                           F/38           Yes                  2                    SGS                              F                            II A
  P8                                           M/49           Yes                  7                    SGS                              F                            II A
  P9                                           M/30           Yes                  14                   SGS                              F                            II A
  P10                                          M/45           Yes                  7                    SGS                              FT                           II A
  P11                                          M/31           Yes                  7                    SGS                              F                            II A
  P12                                          F/40            No                 1800                   --                              F                            II A
  P13                                          M/54            No                 900                    --                              F                            II A
  P14[b](#nt104){ref-type="table-fn"}          M/37            No                 600                    --                              F                            II A
  P15[b](#nt104){ref-type="table-fn"}          M/37            No                 210                    --                              F                            II A
  P16                                          M/47            No                 180                    --                              F                            II A
  P17                                          F/52            No                 270                    --                              FT                           II A
  P18                                          M/21            No                 259                    --                              F                            II A
  P19[b](#nt104){ref-type="table-fn"}          F/34            No                 240                    --                              F                            II A
  P20                                          F/29            No                 240                    --                              F                            II A
  P21                                          M/54            No                 360                    --                              FT                           II A
  P22                                          M/18            No                 360                    --                              F                            II A
  P23                                          M/47            No                 570                    --                              F                            II A

F, frontal; FT, frontal lobe with temporal involvement;

SGS, secondary generalized seizures;

II A, WHO grade II astrocytoma.

PCR samples used for internal validation.

10.1371/journal.pone.0046218.t002

###### Clinical characteristics and univariate analysis of markers predicting pre-operative seizures and seizure control at 6 months after surgery in 83 patients[a](#nt105){ref-type="table-fn"}.

![](pone.0046218.t002){#pone-0046218-t002-2}

  Variable                                                    Seizure Group (n = 47)   No-seizure Group (n = 36)   p Value[b](#nt106){ref-type="table-fn"}                                                                                                  
  ---------------------------------------------------------- ------------------------ --------------------------- ----------------------------------------- ------- --------------- --------------- --------------- --------------------------------------- ---------------------------------------
  No. of patients                                                       46                        32                                 14                       --          32              24               8                          --                                      --
  Male sex                                                           22(47.8)                  15(46.9)                            7(50.0)                   0.845     20(62.5)        15(62.5)         5(62.5)                      1.000                                   0.270
  Median age in yrs (range)                                       38.7 (20--61)               37 (20--58)                        42 (24--61)                 0.125   41.2 (18--56)   40.8 (18--56)   42.3 (20--56)                   0.716                                   0.241
  Tumor location (involved)                                                                                                                                                                                                                                 
  Frontal                                                            24(52.2)                  16(50.0)                            8(57.1)                   0.655     15(46.9)        11(45.8)         4(50.0)                      0.838                                   0.923
  Temporal                                                           26(56.5)                  19(59.4)                            7(50.0)                   0.555     20(62.5)        16(66.7)         4(50.0)                      0.399                                   0.935
  Parietal                                                            1(2.2)                     0(0)                              1(7.1)                    0.126      2(6.3)          2(8.3)           0(0)                        0.399                                   0.407
  Insula                                                             6(13.0)                    5(15.6)                            1(7.1)                    0.432      6(18.8)         4(16.7)         2(25.0)                      0.601                                   0.583
  Tumor pathology                                                                                                                                            0.449                                                                   0.298                                   0.729
  Astrocytoma                                                        27(58.7)                  17(53.1)                           10(71.4)                             16(50.0)        11(45.8)         5(62.5)                                             
  Oligodendroglioma                                                   3(6.5)                    2(6.3)                             1(7.1)                               5(15.6)         3(12.5)         2(25.0)                                             
  Oligoastrocytoma                                                   16(34.8)                  13(40.6)                            3(21.4)                             11(34.4)        10(41.7)         1(12.5)                                             
  Extent of resection                                                                                                                                        0.104                                                   0.008[d](#nt108){ref-type="table-fn"}                    --
  Gross-total                                                        18(39.1)                  15(46.9)                            3(21.4)                             17(53.1)        16(66.7)         1(12.5)                                             
  Subtotal                                                           28(60.9)                  17(53.1)                           11(78.6)                             15(46.9)         8(33.3)         7(87.5)                                             
  KPS score≥80                                                       39(88.6)                  28(93.3)                           11(78.6)                   0.151     26(86.7)        18(81.8)         8(100)                       0.195                                    --
  Radiotherapy                                                       43(95.6)                  29(93.5)                            14(100)                   0.331     28(96.6)        21(95.5)         7(100)                       0.566                                    --
  Chemotherapy                                                       5(11.1)                    4(12.9)                            1(7.1)                    0.569      5(17.2)         4(18.2)         1(14.3)                      0.812                                    --
  High miR-196b expression[c](#nt107){ref-type="table-fn"}           27(58.7)                  19(59.4)                            8(57.1)                   0.887      16(50)         15(62.5)         1(12.5)      0.014[d](#nt108){ref-type="table-fn"}   0.012[d](#nt108){ref-type="table-fn"}

Values represent numbers of patients with percentages in parentheses unless otherwise indicated.

Comparing patients with no history of seizures to those with a history of seizures.

Higher than the average ΔCt values.

Statistically significant.

Management and evaluation of seizures {#s2b}
-------------------------------------

Each patient was routinely prescribed sodium Valproate (0.6--1.2 g/day) at admission regardless of their symptoms. After surgery, patients who presented with or without preoperative seizures were discontinued the same AED after 3 months or 2 weeks, respectively, upon demonstration of seizure-free conditions. For outcome analysis, Engel classification was dichotomized as Class I (completely seizure-free) versus Class II--IV (not seizure-free) [@pone.0046218-Chang1], [@pone.0046218-Engel1] at 6 and 12 months after surgery. For patients with no history of seizure, more than one episode of un-evoked postoperative seizure meant "not seizure-free". Early post-operative seizures (within one week after surgery) were not under consideration for evaluating seizure prognosis. Because better follow-up was available for 6 months, seizure control at this time was the primary endpoint.

RNA preparation {#s2c}
---------------

Total RNA from frozen tumor tissues was extracted using the mirVana miRNA Isolation kit (Ambion, Austin, TX) according to the manufacturer\'s protocol. RNA was quantitated using a ND-1000 UV-VIS Spectrophotometer (NanoDrop Technologies) and the integrity of RNA was assessed with a RNA 6000 Labchip kit in combination with an Agilent 2100 Bioanalyzer (Agilent) according to the manufacturer\'s instructions. RNA samples used in this study all had an OD 260/280 ratio above 1.9 and an RNA integrity number (RIN) greater than 7.0.

MicroRNA expression profiling {#s2d}
-----------------------------

Total RNA was polyadenylated and then converted to cDNA using a biotin-labeled oligonucleotide dT primer with a universal PCR sequence. After cDNA synthesis, miRNA were individually detected using specific oligonucleotides. A single miRNA-specific oligonucleotide (MSO) was designed against each mature miRNA sequence, and miRNA-specific primers were extended using DNA polymerase. Universal primers were used to amplify the cDNA templates and the primer complimentary to the array was fluorescently labeled. The labeled, single-stranded PCR products were hybridized to a Human v2.0 miRNA Expression BeadChip (Illumina Inc., San Diego, CA) with 1,146 human miRNAs (97% coverage of the miRBase 12.0 database).

Quantitative RT-PCR {#s2e}
-------------------

Quantitative RT-PCR was performed using a standard TaqMan PCR kit on an ABI 7900 real-time PCR system (Applied Biosystems, Foster City, CA). All the primers and probes for hsa-miR-196b and U6 rRNA endogenous controls for TaqMan microRNA assays were purchased from Applied Biosystems. Thermal cycling for the quantitative RT-PCR was carried out according to the manufacturer\'s recommendation and the relative expression levels were calculated using the comparative Ct method.

Gene Expression Profiling {#s2f}
-------------------------

Microarray analysis was performed using an Agilent Whole Human Genome Array according to the manufacturer\'s instructions. The integrity of total RNA was checked using an Agilent 2100 Bioanalyzer (Agilent, Santa Clara, USA). The cDNA and biotinylated cRNA were synthesized and hybridized to the array; data were acquired using an Agilent G2565BA Microarray Scanner System and Agilent Feature Extraction Software (v9.1). Probe intensities were normalized using GeneSpring GX 11.0.

Statistical Analysis {#s2g}
--------------------

Associations for miR-196b expression, if considered as a continuous variable, with baseline clinical features were analyzed with Student\'s t-test using GraphPad Prism 4.0. Univariate analyses were carried out using the Chi-square test for dichotomous variables and the Mann-Whitney U-test for continuous non-parametric data. Logistic regression models were constructed to analyze factors related to the probability of post-operative seizure control using SPSS 13.0 for Windows. Gene ontology (GO) analysis was performed using David [@pone.0046218-Huangda1]. A two-sided P-value less than 0.05 was regarded as statistically significant.

Results {#s3}
=======

Association of miR-196b expression with occurrence of pre-operative seizures in LGGs {#s3a}
------------------------------------------------------------------------------------

To underscore the differentially expressed miRNAs between patients with and without pre-operative seizures, 23 samples were subjected to whole genome miRNA profiling ([Figure 1](#pone-0046218-g001){ref-type="fig"}). The differentially expressed genes were identified using SAM analysis. Using a criterion of p\<0.01 and at least 2-fold change, 30 miRNAs were overexpressed and 10 miRNAs were underexpressed resulting in a FDR of 1% ([Figure 2](#pone-0046218-g002){ref-type="fig"}, [Table S1](#pone.0046218.s001){ref-type="supplementary-material"}). Among these miRNAs, miR-196b showed the highest increase (67-fold) in the patients with pre-operative seizures when compared with those without pre-operative seizures, so we choose it for further analysis. Furthermore, an independent cohort containing 83 samples was used to validate the relationship of miR-196b and the occurrence of pre-operative seizures. As shown in [Figure 3A](#pone-0046218-g003){ref-type="fig"}, patients with pre-operative seizures demonstrated higher expression levels of miR-196b when compared with those without seizures (p\<0.001, Student\'s t-test). To evaluate the possible diagnostic role of miR-196b for occurrence of pre-operative seizures, receiver operating characteristic (ROC) curve analysis was performed ([Figure 3B](#pone-0046218-g003){ref-type="fig"}). The area under the curve was 0.965.

![Heat map of the differentially expressed genes identified using SAM analysis (Q value \<1%) showing 30 overexpressed and 10 underexpressed miRNAs in seizure group.](pone.0046218.g002){#pone-0046218-g002}

![Association of miR-196b expression by qPCR with the occurrence of pre-operative seizures in LGGs.\
(A) Patients with pre-operative seizures exhibited higher expression levels of miR-196b when compared with those without pre-operative seizures. (B) The diagnostic role of miR-196b for determining the occurrence of pre-operative seizures using receiver operating characteristic curve analysis.](pone.0046218.g003){#pone-0046218-g003}

Association of miR-196b expression with seizure control after surgery in patients without pre-operative seizures {#s3b}
----------------------------------------------------------------------------------------------------------------

In the validation cohort of our study, all patients were subjected to sodium Valproate monotherapy pre- and post-operatively. As shown in [Table 2](#pone-0046218-t002){ref-type="table"}, 32 of 46 patients with follow-up in seizure group and 24 of 32 patients with follow-up in non-seizure group were taken off sodium valproate in 3 months and 2 weeks after surgery respectively. In univariate analysis, extent of tumor resection and expression of miR-196b (p = 0.008 and 0.014, respectively, Chi-square test) were significantly correlated with seizure control in patients without pre-operative seizures. These 2 dichotomous variables were then entered into the multivariate analysis (using logistic regression analysis). Both of them showed significance (p = 0.007 and 0.015, respectively, [Table 3](#pone-0046218-t003){ref-type="table"}). This indicates that higher miR-196b expression levels increased the odds that sodium Valproate treatment in patients without pre-operative seizures would be ineffective. However, in patients with pre-operative seizures, no similar results were observed. The predictive power of miR-196b expression can also be observed in the ROC curve ([Figure 4](#pone-0046218-g004){ref-type="fig"}), with an area under the curve of 0.94.

![Association of miR-196b expression by qPCR with post-operative seizure control in patients without pre-operative seizures.\
(A) The predictive power of miR-196b expression in all patients. (B) The predictive power of miR-196b expression in all patients without pre-operative seizures. (C) The predictive power of miR-196b expression in all patients with pre-operative seizures.](pone.0046218.g004){#pone-0046218-g004}

10.1371/journal.pone.0046218.t003

###### Multivariate predictors of seizure control at 6 months after surgery in the patients without pre-operation seizures[\*](#nt109){ref-type="table-fn"}.

![](pone.0046218.t003){#pone-0046218-t003-3}

  Variable                      OR         95%CI        p Value
  -------------------------- -------- ---------------- ---------
  Gross-total resection       14.680   1.300--165.793    0.007
  High miR-196b expression    0.081     0.007--0.936     0.015

Results of logistic regression analysis.

Biological Insights of miR-196b {#s3c}
-------------------------------

To further understand the potential functional role of miR-196b expression in low-grade gliomas, we performed a GO analysis. Biological processes that relate to transcription and cell cycles were over-represented in the miR-196b-associated gene expression signature ([Table 4](#pone-0046218-t004){ref-type="table"}). To gain insights into the functional contribution of miR-196b expression levels tumor-related epilepsy, we derived a gene expression signature associated with miR-196b expression in 22 patients using whole genome mRNA profiling. We observed that the expression of 1423 probe sets significantly correlated (R\>0.4 or \<−0.4; p\<0.05) with that of miR-196b; 312 probe sets negatively correlated and 1111 probe sets positively correlated ([Figure 5](#pone-0046218-g005){ref-type="fig"}, [Table S2](#pone.0046218.s002){ref-type="supplementary-material"}). Among these genes, we observed a positive correlation of miR-196b expression with the expression of proliferation-associated genes, such as PCNA.

![Heat map of the derived gene-expression signature correlated with miR-196b expression.\
Total 312 negatively correlated probe sets (R\<−0.4; p\<0.05) and 1111 positively correlated probe sets (R\>0.4; p\<0.05) with miR-196b were included. Columns represent patients and rows represent probes. Patients are ordered from left to right by increasing miR-196b expression. Probes are ordered by unsupervised clustering using Cluster 3.0. Arrows indicate gene that was discussed in the text (PCNA).](pone.0046218.g005){#pone-0046218-g005}

10.1371/journal.pone.0046218.t004

###### Biological processes significantly over-represented in the miR-196b expression profile.

![](pone.0046218.t004){#pone-0046218-t004-4}

  GO ID                       GO Terms                    Count   Fold Enrichment   p Value
  --------- -------------------------------------------- ------- ----------------- ----------
  0006350                  transcription                   200       1.890995       5.24E−21
  0045449           regulation of transcription            217       1.657318       8.72E−16
  0051252       regulation of RNA metabolic process        165       1.807893       6.49E−15
  0006355    regulation of transcription, DNA-dependent    161       1.803863       1.96E−14
  0051301                  cell division                   51        3.434272       2.35E−14
  0007049                    cell cycle                    89         2.27832       2.89E−13
  0000279                     M phase                      49        2.958603       2.23E−11
  0022403                 cell cycle phase                 55        2.639057       9.75E−11
  0048285                organelle fission                 37        3.209613       9.57E−10
  0007067                     mitosis                      36        3.250621       1.18E−09
  0000280                 nuclear division                 36        3.250621       1.18E−09
  0022402                cell cycle process                64        2.250184       1.84E−09
  0000087          M phase of mitotic cell cycle           36        3.192574       1.94E−09
  0000278                mitotic cell cycle                47         2.52338       1.16E−08
  0006281                    DNA repair                    37        2.588033       2.91E−07

Discussion {#s4}
==========

Tumor-related epilepsy is among the most common types of symptomatic epilepsy. Many recent studies have demonstrated dysregulated miRNAs in human TLE and post status epilepticus rats [@pone.0046218-Aronica1], [@pone.0046218-Song1], [@pone.0046218-Hu1]. This strongly suggests some miRNA expression patterns may contribute to the epileptogenesis process. Our study provides the first report of quantitative global miRNA expression profiles in low-grade gliomas from clinical tissue samples, and showed an aberrant miRNA expression pattern.

MiR-196b and tumor malignancy {#s4a}
-----------------------------

Currently, microarray profiles of miRNA expression patterns have shown that the highest expression levels of miR-196b were found in human bone marrow and spleen cells [@pone.0046218-Baskerville1]. In the central nervous system (CNS), miR-196b has been identified as a candidate oncogene for tumor cells because of the fact that it is expressed at higher levels in CNS tumor-derived cell lines compared with normal brain cells [@pone.0046218-Gaur1]. Increased miR-196 expression levels, relative to their matched normal tissues, have also been reported in a recent study [@pone.0046218-Szafranska1], further supporting the relevance of miR-196 to gliomas. In addition, miR-196b may play a role in the malignant progression of gliomas and may be a prognostic predictor in GBMs [@pone.0046218-Guan1], [@pone.0046218-Lakomy1]. These findings suggest that up-regulation of miR-196 could contribute to tumorigenesis and malignant progression, and may have diagnostic and prognostic significance for gliomas. However, there are other reports indicating that miR-196 may play a tumor suppressive role [@pone.0046218-Braig1], [@pone.0046218-Li1].

MiR-196b and seizures {#s4b}
---------------------

The mechanisms of action for miR-196 in tumor-related epilepsy are still unknown. These may depend on the biological processes underlying miR-196. In the present study, firstly, miR-196b correlates with seizure occurrence. Now, some studies have demonstrated that patients with epilepsy are more likely to have worse seizure control after surgery than those without pre-operative epilepsy [@pone.0046218-Chang1]. It is possible that high levels of miR-196b expression, implying a potentially strong proliferation of tumor cells, also suggest a high risk of epileptic susceptibility. Second, miR-196b expression correlates with seizure control. Based on the fact that seizure recurrence is generally associated with tumor progression [@pone.0046218-Chang1], [@pone.0046218-Chaichana1], we hypothesize that proliferation of tumor cells plays a necessary role in seizure occurrence. Thus, if high levels of miR-196b expression cause epilepsy by enhancing the proliferation of tumor cells, it could be reasonably explained that glioma patients with strong miR-196b expression have poor seizure prognosis.

MiR-196b and cell proliferation {#s4c}
-------------------------------

We observed a positive correlation of miR-196b expression with the expression of proliferation-associated genes. This further suggests that the proliferation of tumor cells could possibly play a part in the pathogenesis of tumor-related epilepsy. GO analysis showed that many cell cycle-associated gene sets were over-represented in the miR-196b-associated gene expression signature. The expression of PCNA, a proliferation marker, was also positively correlated with miR-196b expression. These results suggest that miR-196 may obtain its biological role by regulating cell proliferation.

MiR-196b and Valproate acid {#s4d}
---------------------------

Valproate acid (VPA), a stabilizer of the cell membrane and an inhibitor of GABA receptors controlling epileptic discharge, has the potential for apoptosis, growth arrest, and cell differentiation of tumor cells through inhibition of histone deacetylase [@pone.0046218-Eyal1], [@pone.0046218-Li2]. Weller et al. indicated the potential anti-tumor activity of VPA in patients with glioblastoma who require an AED during temozolomide-based chemoradiotherapy [@pone.0046218-Weller1]. In the present study, miR-196b expression could be considered in some way as a predictor of the efficacy of sodium Valproate in patients without pre-operative epilepsy. The association between miR-196b expression and sodium Valproate response suggests that sodium Valproate mediates the clinical effects of some molecules targeted by miR-196b. The way in which miR-196b regulates the binding of sodium Valproate and leads to seizure reduction is not clear. Additional investigations of functional analysis, particularly on its possible contribution to tumor proliferation, should be conducted to validate the role of miR-196b in tumorigenesis and the malignant progression of glioma. Further understanding of how cell proliferation contributes to the epileptogenesis process will require the development of suitable animal models. If this hypothesis holds, assessment of miR-196b expression in brain tissue (or possibly blood samples in future) of epilepsy patients with glioma might guide the selection of those patients who have a high probability of responding to sodium Valproate.

Other miRNAs and seizures {#s4e}
-------------------------

Currently, changes in the expression of miR-146a have been implicated in both the development of multiple cancers and in the regulation of inflammation induced via the innate immune response [@pone.0046218-Williams1], [@pone.0046218-Nahid1]. Aronica et al. indicated that an increased expression of miR-146a was observed in a rat model of TLE as well as in human TLE [@pone.0046218-Aronica1]. Our microarray data also reveals that miR-146a is up-regulated in patients with preoperative seizures. However, further investigation is needed to confirm the role of inflammation in tumor-related seizures.

MiR-15b, another miRNA found in our microarray data, is also reported in several similar studies on GBM [@pone.0046218-Guan1], [@pone.0046218-Xia1]. These authors indicated miR-15b was overexpressed in GBM cells compared with normal controls. Moreover, miR-15b was identified in the cerebrospinal fluid as a biomarker for the diagnosis of glioma [@pone.0046218-Baraniskin1]. Future studies are warranted to characterize its possible mechanism causing seizures.

Additionally, as shown previously, we demonstrated a relationship between extent of resection and seizure prognosis in patients without a history of seizure. It is generally accepted that minimizing the residue volume of tumors with gross total resection could increase the possibility of removing the epileptogenic zone. Thus, patients are more likely to achieve favorable seizure control.

The current study has some limitations. Six or 12 months follow-up is a relatively short period of time for estimating seizure frequency, a longer follow-up would have been preferable when survival information is available. We did not use a control group to evaluate the response to another or newer AEDs such as levetiracetam. Further confirmation on large-scale prospective data would be advantageous.

Conclusions and perspectives {#s4f}
----------------------------

Our data suggest that high miR-196b expression levels are a novel and valuable marker for the molecular diagnosis and prediction of glioma-related epilepsy. Prospective controlled studies are needed to address this issue. *In vivo* experiments to determine the exact role of miR-196b in tumor proliferation could contribute to explaining epileptogenesis and developing new treatment strategies aimed at improving patients\' quality of life.
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